Hemodialysis Bloodline Systems Market Size, Share and Global Trend by Product Poly Vinyl, Chloride (Pvc) Haemodialysis Bloodline Systems, Polyethylene (Pvc) Haemodialysis Bloodline Systems, Polypropylene (Pp) Hemodialysis Bloodline Systems, ABS hemodialysis bloodline systems), By Therapy Type (Double Needle Therapy, Single Needle Therapy, Single Needle), By End User (Hospitals, Clinics, Home Care Settings), and Regional Forecast, 2024-2032

Renal replacement therapies performed among patients with improper kidney function include kidney transplant, peritoneal dialysis, and hemodialysis. Among them, hemodialysis is a process of purifying blood while removing the waste materials such as urea and creatinine from the body. This helps in the regulation of blood pressure along with managing mineral balance.

Growing prevalence of chronic kidney diseases, end-stage renal disease (ESRD), renal failure, and others across the globe are likely to boost the demand for hemodialysis bloodline systems during the forecast period. Growing research and development activities resulting in the development of innovative products are likely to increase the adoption of the hemodialysis bloodline systems by the physicians. For instance, in April 2018, Fresenius Medical Care AG & Co. KGaA, a leading provider of bloodline systems, won the Red Dot Award for its Product Design for the company’s 6008 CAREset indicating satisfactory therapeutic merits.

The growth in global hemodialysis bloodline market is being driven by the increase in the prevalence of chronic kidney disease (CKD) as well as end-stage renal disease (ESRD), increase in cases of renal complications due to diabetes, improved government-aided health reimbursement. According to the National Chronic Kidney Disease Fact Sheet, in 2017, nearly 30 million U.S. population was estimated to have chronic kidney disease (CKD), which accounted for 15% of the U.S. population. However, the high cost of the overall dialysis process, comparatively less healthcare spending in emerging regions, and lack of healthcare awareness are some of the factors likely to hinder the market growth during the forecast period. 

Key Players Covered: 

Some of the major companies that are present in the global hemodialysis bloodline systems market are Baxter, B. Braum Melsungen AG, NIPRO, Bioteque Corporation, Allmed Medical Care Holdings Limited, Fresenius Medical Care Australia Pty Ltd, Weigao Group, Sunder Biomedical Tech Co., Ltd., Asahi Kasei Medical Co., Ltd., among others. 

SEGMENTATION 

In terms of product, the Poly Vinyl chloride (PVC) hemodialysis bloodline systems are likely to hold major market share owing to its availability and high acceptance due to its affordability. Among end-users, the homecare settings are anticipated to expand at the highest CAGR during the forecast period. 

Key Insights 

• Epidemiology Analysis of Renal Disorders by key countries
• The regulatory scenario for key countries
• Reimbursement Scenario for key countries
• Recent industry developments such as partnerships, mergers, and acquisitions
• Key performance indicators for global radiofrequency ablation systems market 

Regional Analysis: 

The global hemodialysis bloodline systems market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to hold a considerable share of the global hemodialysis bloodline systems market owing to the high prevalence of chronic kidney diseases. According to the report by World Health Organization (WHO), high-income countries typically spend more than 2–3% of their annual health-care budget on the treatment of end-stage kidney disease, even though those receiving such treatment represent under 0.03% of the total population. Asia Pacific is projected to expand at a significantly high growth rate attributable to a surge in the economy, growing awareness among the population in the region, and expansion of footprints by leading players in the region.

Key Industry Developments     

• In February 2019, B. Braun Medical Inc. announced the acquisition of the Medisystems Streamline Bloodlines business. The acquired bloodline systems will include the Streamline Bloodline for the Dialog+ hemodialysis system, Streamline Bloodline for the Fresenius Medical Care hemodialysis system, and Streamline Bloodline Long for the Fresenius Medical Care hemodialysis system.
• In February 2019, the Fresenius Medical Care AG & Co. KGaA completed the $2bn acquisition of US-based medical devices maker NxStage Medical involved in the development, production, and marketing of medical devices for in-home dialysis and critical care.